New business models for antibiotic innovation.
Abstract
The increase in antibiotic resistance and the dearth of novel antibiotics have become
a growing concern among policy-makers. A combination of financial, scientific, and
regulatory challenges poses barriers to antibiotic innovation. However, each of these
three challenges provides an opportunity to develop pathways for new business models
to bring novel antibiotics to market. Pull-incentives that pay for the outputs of
research and development (R&D) and push-incentives that pay for the inputs of R&D
can be used to increase innovation for antibiotics. Financial incentives might be
structured to promote delinkage of a company's return on investment from revenues
of antibiotics. This delinkage strategy might not only increase innovation, but also
reinforce rational use of antibiotics. Regulatory approval, however, should not and
need not compromise safety and efficacy standards to bring antibiotics with novel
mechanisms of action to market. Instead regulatory agencies could encourage development
of companion diagnostics, test antibiotic combinations in parallel, and pool and make
transparent clinical trial data to lower R&D costs. A tax on non-human use of antibiotics
might also create a disincentive for non-therapeutic use of these drugs. Finally,
the new business model for antibiotic innovation should apply the 3Rs strategy for
encouraging collaborative approaches to R&D in innovating novel antibiotics: sharing
resources, risks, and rewards.
Type
Journal articleSubject
3Rs strategyantibiotic innovation
antibiotic resistance
business models
delinkage
Anti-Bacterial Agents
Models, Theoretical
Permalink
https://hdl.handle.net/10161/8997Published Version (Please cite this version)
10.3109/03009734.2014.898717Publication Info
So, Anthony D; & Shah, Tejen A (2014). New business models for antibiotic innovation. Ups J Med Sci, 119(2). pp. 176-180. 10.3109/03009734.2014.898717. Retrieved from https://hdl.handle.net/10161/8997.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Anthony Deh-Chuen So
Visiting Professor of the Practice in the Sanford School of Public Policy
Dr. Anthony So joined Duke University’s Sanford School of Public Policy in 2004 as
director of a new Program on Global Health and Technology Access. The program focuses
on issues of globalization and health, particularly innovation and access to essential
medicines for those in developing countries. The program works as the Strategic Policy
Unit for ReAct, a global coalition dedicated to combating antibiotic resistance. Dr.
So's research on the ownership of knowledge and how it is best h

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info